Full Press Release Details
Unicycive Therapeutics
Announces Time Change for 2025 Annual Meeting of Stockholders
LOS ALTOS, CA May 21, 2025/ Unicycive
Therapeutics, Inc. (NASDAQ: UNCY) ("Unicycive" or the "Company"), a clinical
stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual
Meeting of Stockholders (the "Annual Meeting"). The previously announced date of the meeting (June 9, 2025) and location
of the meeting (4300 El Camino Real, Suite 210, Los Altos, CA 94022) will not change, but the meeting will be held at 7:00 a.m., Pacific
Daylight Time, on that date. Stockholders of record as of the close of business on April 30, 2025, the record date, can find additional
details regarding participation in the Annual Meeting at https://annualgeneralmeetings.com/uncy2025.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a
novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia
in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for
the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention
of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers.
SOURCE: Unicycive Therapeutics, Inc.